Menten AI

paid

Menten AI's MAUD 1.0 platform uses generative AI, physics-based models, and quantum simulations to design peptide macrocycles de novo for complex drug targets with >90% hit rate.

Research & Education

Foundation Models

AI Research Tools

About

Menten AI is at the forefront of applying generative artificial intelligence to pharmaceutical drug discovery, specifically targeting the design of peptide macrocycles. Their proprietary platform, MAUD 1.0 (Macrocycle AI Unified Design), enables de novo generation of drug-like peptides for complex and historically intractable biological targets, such as Protein-Protein Interfaces. Unlike traditional high-throughput screening approaches, MAUD 1.0 integrates generative AI with physics-based computational models and quantum simulations to design and optimize candidate molecules with validated drug-like properties—including nanomolar-level potency, oral bioavailability, and cell-permeability. The platform boasts a greater than 90% hit rate across the preclinical discovery pipeline, dramatically reducing the time and cost associated with early-stage drug development. Menten AI partners with top-10 global pharmaceutical companies and is backed by leading venture capital investors, positioning it as a trusted technology provider for next-generation drug discovery programs. Their approach expands the accessible chemical space for peptide therapeutics, opening doors to drug targets previously considered undruggable. The platform is designed for pharmaceutical research teams, biotech startups, and academic drug discovery programs seeking to leverage AI to accelerate candidate identification and optimization. Menten AI also publishes scientific research and offers partnership programs for organizations looking to integrate cutting-edge generative AI into their discovery workflows.

Key Features

De Novo Peptide Macrocycle Design: MAUD 1.0 generates peptide macrocycles from scratch for complex drug targets, including Protein-Protein Interfaces previously considered undruggable.
Physics-Based and Quantum Simulation Integration: Combines generative AI with physics-based computational models and quantum simulations to ensure chemically valid, optimized drug candidates.
>90% Hit Rate Across Preclinical Pipeline: Validated performance across the preclinical discovery pipeline with demonstrated nanomolar potency, oral bioavailability, and cell-permeability.
Expanded Chemical Space: Accelerates discovery by exploring a far broader chemical space than traditional screening, enabling access to novel drug scaffolds.
Pharma Partnership Program: Offers structured partnership programs for top pharmaceutical and biotech companies to integrate MAUD 1.0 into their drug discovery workflows.

Use Cases

Designing de novo peptide macrocycle drug candidates for previously undruggable Protein-Protein Interface targets in oncology or immunology
Accelerating preclinical drug discovery programs by generating optimized lead candidates with validated potency and bioavailability profiles
Partnering with top pharmaceutical companies to augment traditional medicinal chemistry pipelines with AI-driven macrocycle design
Exploring novel chemical scaffolds beyond the reach of traditional small molecule or biologic approaches for complex diseases
Streamlining early-stage drug discovery workflows through AI-guided candidate optimization, reducing time and cost to clinical readiness

Pros

Validated Drug-Like Properties: MAUD 1.0 has demonstrated nM-level potency, oral bioavailability, and cell-permeability, providing high-confidence candidates for preclinical development.
Trusted by Top-Tier Pharma: Partnerships with top-10 global pharmaceutical companies signal strong industry validation and real-world applicability of the platform.
Addresses Undruggable Targets: Capable of designing candidates for challenging Protein-Protein Interfaces, opening new therapeutic opportunities beyond traditional small molecules.

Cons

Not Self-Serve: The platform operates through partnership agreements rather than direct self-service access, limiting availability to organizations that engage with Menten AI directly.
Highly Specialized Domain: Focused exclusively on peptide macrocycles and pharmaceutical drug discovery, making it unsuitable for general-purpose AI or non-biotech applications.

Frequently Asked Questions

MAUD 1.0 (Macrocycle AI Unified Design) is Menten AI's generative AI platform for designing peptide macrocycles de novo. It combines generative AI, physics-based models, and quantum simulations to produce drug-like candidates for complex biological targets.

MAUD 1.0 is designed to tackle complex drug targets, including Protein-Protein Interfaces (PPIs), which are historically difficult to address with traditional small molecules or screening approaches.

The platform has demonstrated nanomolar-level potency, oral bioavailability, and cell-permeability in its designed candidates, along with a greater than 90% hit rate across the preclinical discovery pipeline.

Menten AI works with pharmaceutical companies, biotech startups, and research organizations through partnership programs. Access is not self-serve; interested parties can reach out via the Partner with Us program on their website.

Unlike traditional high-throughput screening which tests large libraries of existing compounds, MAUD 1.0 generates novel peptide macrocycles from scratch using generative AI integrated with physics-based and quantum simulation methods, significantly expanding the accessible chemical space and accelerating discovery timelines.